BioNTech SE
BNTX
$93.66
$0.320.34%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -87.17% | -40.52% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -87.17% | -40.52% | |||
| Cost of Revenue | -76.75% | 103.30% | |||
| Gross Profit | -92.39% | -56.08% | |||
| SG&A Expenses | -31.78% | 46.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -89.33% | -73.47% | |||
| Total Operating Expenses | -34.90% | -22.37% | |||
| Operating Income | -121.86% | -813.04% | |||
| Income Before Tax | -146.28% | -1,016.70% | |||
| Income Tax Expenses | -145.99% | 44.69% | |||
| Earnings from Continuing Operations | -71.92% | -958.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -71.92% | -958.16% | |||
| EBIT | -121.86% | -813.04% | |||
| EBITDA | -106.69% | -391.45% | |||
| EPS Basic | -65.62% | -937.13% | |||
| Normalized Basic EPS | -161.15% | -595.33% | |||
| EPS Diluted | -65.62% | -937.13% | |||
| Normalized Diluted EPS | -161.15% | -595.33% | |||
| Average Basic Shares Outstanding | 3.81% | 2.02% | |||
| Average Diluted Shares Outstanding | 3.81% | 2.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||